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The Criminalization of Medicinal Marijuana
The Hastings Women's Law Journal Symposium, "The Resurgence of
Herbal Remedies: Controlling Access to Herbal Supplements and Medici-
nal Marijuana," was held at Hastings College of the Law on February 6,
1999. Following are the Symposium speeches given during Panel II,
"Criminalization of Medicinal Marijuana. " Hastings Women's Law Jour-
nal staff edited for clarity, researched and added footnotes to the text of the
speeches. The Journal wishes to thank Sarah L. Ream for her editorial
work, and Christopher Leung, Karolyn Plummer, Samantha Rajaram,
Penelope Shaner-Gaffney and Claudia Spielman for their work on the foot-
notes.
STEVEN HEILIG, MODERATOR'
Hello, my name is Steve Heilig, I'm the moderator today probably be-
cause I am somewhat of the spokesperson for the local medical association.
I was very involved in both the political lobbying around Proposition 2152
1. Steven Heilig served as the moderator for Panel II of the Symposium. Steven Heilig
is currently Director of Public Health and Education for the San Francisco Medical Society.
He is also co-founder and Director of the Bay Area Network of Ethics Committee, a profes-
sional educational and policy making association.
2. Proposition 215, effective November 6, 1996, added section 11362.5 to the California
Health and Safety Code, as follows:
(a) This section shall be known and may be cited as the Compassionate
Use Act of 1996.
(b)(1) The people of the State of California hereby find and declare that
the purposes of the Compassionate Use Act of 1996 are as follows:
(A) To ensure that seriously ill Californians have the right to obtain
and use marijuana for medical purposes where that medical use is
deemed appropriate and has been recommended by a physician who has
determined that the person's health would benefit from the use of mari-
juana in the treatment of cancer, anorexia, AIDS, chronic pain, spastic-
ity, glaucoma, arthritis, migraine, or any other illness for which mari-
juana provides relief.
(B) To ensure that patients and their primary caregivers who obtain
and use marijuana for medical purposes upon the recommendation of a
physician are not subject to criminal prosecution or sanction.
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and then trying to implement it initially when it was first passed and every-
body was scrambling to figure out what medical marijuana was all about.
Let me start with a little story, a true story. The other day on Haight Street,
which is my neighborhood, I was handed a little orange flyer which said:
"Announcing under new management San Francisco Patient and Care-
giver's Health Center. Medical marijuana everyday 3:00 to 7:00 p.m. Ho-
listic massage Saturday and Sunday 3:00 to 7:00 p.m. A hassle free safe
medical cannabis facility. $5.00 off first order with this coupon."
So we had, until it was shut down by authorities, very close to where
we are today a "buyer's club" that is no longer in existence. I was inter-
ested to see this flyer because apparently the closed facility is operating
under new management. I was coming up from San Francisco General
Hospital from a meeting Thursday, I was in the neighborhood and so I
thought I would stop by. I had the coupon even. So, I parked and ran the
gauntlet of people purveying all sorts of chemicals dangerous or otherwise,
ranging from heroin and syringes to alcohol and tobacco, and came to this
little storefront. The fellow looked at me through the cage that locked the
door and then buzzed me in, thought I looked all right I guess. Then I was
welcomed in through the glass door and sat down in a big cloud of smoke.
I started to get a second-hand buzz as it were, as I tried to see what I could
get there-what did I need to do? The guy just handed me some forms and
said, "Fill these out." But then he looked at me, and unfortunately he
"made me," as they say in the business and said, "I know you from some-
where and you don't want this."
But anyway, what we have now is this legally and medically question-
able gray area that has been heightened ever since Proposition 215. The
main irony of Proposition 215 is that it made things a lot less clear in some
ways about what is legal to do regarding marijuana in a medical and clini-
(C) To encourage the federal and state governments to implement a
plan to provide for the safe and affordable distribution of marijuana to
all patients in medical need of marijuana.
(2) Nothing in this section shall be construed to supersede legislation
prohibiting persons from engaging in conduct that endangers others, nor
to condone the diversion of marijuana for non-medical purposes.
(c) Notwithstanding any other provision of law, no physician in this
state shall be punished, or denied any right or privilege, for having rec-
ommended marijuana to a patient for medical purposes.
(d) Section 11357, relating to the possession of marijuana, and Section
11358, relating to the cultivation of marijuana, shall not apply to a pa-
tient, or to a patient's primary caregiver, who possesses or cultixates
marijuana for the personal medical purposes of the patient upon the
written or oral recommendation or approval of a physician.
(e) For purposes of this section, "primary caregiver" means the individ-
ual designated by the person exempted under this section who has con-
sistently assumed responsibility for the housing, health, or safety of that
person.
CAL. HEALTH & SAFETY CODE § 1132.5 (West 2000).
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cal setting. A lot of doctors I have talked with through the years have said
that they are much more reluctant to talk about, or recommend, marijuana,
for whatever symptoms, than they were before it became supposedly legal
in this state. These questions are some of the things you are going to hear
about today. Is there really a medical use for the drug? It depends on who
you ask. If you ask our drug czar' he'll say that it's "Cheech and Chong"
medicine and there is no use for it. And is it legal? Well, if you ask some
people at the federal level, they'll say, "No, under no circumstances."
Some people at the state will tell you, "Either way, depends on who's in
office."
So, we have quite a gray area, interestingly it's all about a plant first
mentioned in written history 5,000 years ago. Chinese and Indian texts
talked about it for various medicinal uses. Nowadays you have the same
debate. You have some, like longtime marijuana activist Dennis Peron,3
who was one of the authors of Proposition 215 and has now retired to his
farm up in Humboldt County, saying that all marijuana use is medicinal
and anybody who smokes this stuff is doing it to medicate themselves for
some reason. On the other hand, you have people who would say there is
no legitimate medicinal use.
I'm not going into those questions because we have people here who
are going to go into those questions in somewhat more depth and better
than I could. We're going to hear the medical side of this first and I'm very
glad that Dr. Donald Abrams is here. I want you to know that if you could
have anybody come to talk about this, he is the only person in this country
right now who now has actual approved legitimate research underway.
Before medical marijuana became a big issue though, he was already
very well known. I can assure you he's neither Cheech nor Chong; he is a
full professor of medicine at the University of California, and has co-run
the AIDS program at San Francisco General, which if you ask anybody in
the know there is no place better in the world to go if you want treatment
for HIV. He has also run an organization called the Community Consor-
tium which has brought together AIDS clinicians of all different types to
conduct research and do various projects that have been very well respected
and well known all over the world in that field. So, Dr. Abrams is first
going to tell us about the real medical story of marijuana.
3. Dennis Peron is a Vietnam Veteran, author of Proposition 215 and founder of the
San Francisco Cannabis Cultivators Club that distributed medicinal marijuana to people
with AIDS-related diseases, cancer, multiple sclerosis and other painful afflictions. See
Rick DelVecchio, Pot Club Plea-Morally Not Guilty,' S.F. CHRON., Oct. 30, 1996, at A13;
see also CALIFORNIANS FOR COMPASSIONATE USE, Medical Marijuana Resources (visited
Mar. 10, 2000) <http://www.marijuana.org/peron57.html>.
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DR. DONALD ABRAMS4
Thank you, I don't know if I'll do all of that but, as Steve mentioned,
marijuana has been used for a millennium in treatment of diseases, and was
first introduced into Western medicine in the 1840s by a Dr. W. B.
O'Shaughnessys in the British Isles. He said that marijuana had many
properties against pain, inflammation. It was anti-spasmodic, anti-seizure,
an everything sort of drug. With such a broad array of activity, people
could be concerned it might be akin to snake oil or something that is not
real.
Marijuana use began to drop, or cannabis as it was known, began to
drop off at the beginning of the 1900's when actual agents that could do all
of these other indications against pain and helping people sleep became
available for the first time, as well as aspirin and syringes. So our ability to
treat was expanded and the use of cannabis declined. In 1937 the Federal
Government imposed the Marijuana Tax Act which imposed a dollar an
ounce tax on people using marijuana for medicinal purposes and a hundred
dollars an ounce tax for people using marijuana for recreational purposes.
Interestingly, the American Medical Association at the time was virtu-
ally alone in opposing this Act because they thought there was no evidence
that marijuana was harmful as a medicine, and that this Act would impede
further research into the therapeutic benefits. In 1970 marijuana was clas-
sified as a Schedule I substance in the Controlled Substance Act,7 along
with drugs such as heroin, LSD, amphetamines, etc. So, that's where
marijuana has been, requiring a special license to be prescribed. But again,
the medical utilization of marijuana has declined and really disappeared to
nothing.
Clinical research of the effectiveness of marijuana in various condi-
tions is very poor. Most of the studies were done in the 1960's and 70's,
before we had the availability of the technology that we have today. We
4. Dr. Donald Abrams received his M.D. from Stanford University. He is currently As-
sistant Director of the AIDS Program at San Francisco General Hospital, and Chairman of
the Community Consortium (the Bay Area's community-based HIV clinical trials organiza-
tion). Dr. Abrams has performed extensive cancer and AIDS research, teaching and clinical
practice for the past twenty years. He is currently involved in the only federally approved
study researching the potential medicinal benefits of marijuana inhalation for AIDS patients.
5. William Brooke O'Shaughnessy, On the Preparations of the Indian Hemp, or Gunjay,
reprinted in MARIJUANA: MEDICAL PAPERS, 1839-1972 3 (Tod H. Mikuriya ed., Medi-Comp
Press 1973). Dr. O'Shaughnessy was Assistant-Surgeon, and Professor of Chemistry at the
Medical College of Calcutta and an early proponent of medicinal marijuana. See id.
6. Marihuana Tax Act of 1937, Pub. L. No. 75-238, ch. 553, 50 Stat. 551 (1937), re-
pealed by Internal Revenue Code Act of 1939, ch. 4, 53 Stat. 1. A nearly exact copy of the
1937 Act was resurrected in 1939 and codified as 26 U.S.C. § 2593(a). In 1954, it was re-
numbered as Section 4744(a). The Marihuana Tax Act was ultimately repealed by the
Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No. 91-513,
§ 1101(b)(3)(A), 84 Stat. 1236, 1292 (1970) (codified at 21 U.S.C. §§ 801 etseq.)
7. 21 U.S.C. § 812(a); see generally id. §§ 801-971 (1981).
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found ourselves in San Francisco in a unique situation. My group, The
Community Consortium, does what is called community-based clinical tri-
als. One of the things that inspires us to do clinical trials is if patients are
using something in the community we want to know if it works or not.
We did this with inhaled Pentamadine,8 a treatment to prevent the
AIDS pneumonia that was very popular in the early 1980's. People were
using it; we had no idea if it worked, so we established a clinical trial. We
found out it worked, got published as a lead article in the New England
Journal of Medicine,9 and it also led to the FDA approving this as a
mechanism to prevent this pneumonia.
In the beginning of the 1990's we found ourselves in a similar situa-
tion. Patients were telling us that smoking marijuana was helpful to them,
particularly patients who were suffering from the AIDS wasting syn-
drome.'0 In the mid-80's, an extract of marijuana, Delta-9-THC (the main
psychoactive component) became available as a prescribed drug-Man-
nol® (or dronabinol)." Marijuana itself has more than three hundred com-
pounds but the single most psychoactive ingredient, Delta-9-THC, a
Schedule II substance, was licensed and became a prescribable drug. This
was approved originally in the mid-80's for treating nausea and vomiting
secondary to chemotherapy.' 2 In 1992, the indication was expanded for
Marinol® to include treating patients with the AIDS wasting syndrome and
it was moved to Schedule lIl.1
3
Now, many of you look a little too young to remember AIDS six or
seven years ago, but it was a different disease then. Many patients died of
this wasting syndrome where they developed loss of appetite and nausea.
They could not eat, and they became skeletal and wasted away. Patients
were getting the benefit of increased appetite, decreased pain and decreased
depression if they were smoking marijuana.
Everybody said, "Why do you need to smoke marijuana when we have
8. Pentamadine is an antibiotic used in the treatment of pneumocystis carinii. See Tim
PHYSICIAN'S DESK REFERENCE FAMILY GUIDE TO PRESCRIPTION DRUGS 845 (David W. Sifton
et al. eds., 1993).
9. See G.S. Leoung et al., Aerosolized Pentamidine for Prophylaxis Against Pneumo-
cystis Carinii Pneumonia-the San Francisco Community Prophylaxis Trial, 323 NEW ENG.
J. MED. 769 (1990).
10. See CURRENT MEDICAL DIAGNOSIS AND TREATMENT 1271 (Lawrence M. Tierney, Jr.
et al. eds., 39th ed. 2000) (defining AIDS wasting syndrome as decreased appetite and
weight loss in AIDS patient suffering from anorexia, nausea, vomiting, nutritional malab-
sorption and/or heightened metabolic rate).
11. Marinol® is a brand name and Dronabinol is the generic name for an anti-nausea and
appetite stimulant medication. See H. WINTER GRIFFTH, COMPLETE GUIDE TO PRESCRIPTION
AND NON-PRESCRIPTION DRUGS 334 (1999)
12. See Schedules of Controlled Substances: Rescheduling of the Food and Drug Ad-
ministration Approved Product Containing Synthetic Dronabinol, 64 Fed. Reg. 35928,
35928 (1999) (to be codified at 21 C.F.R. §§ 1308, 1312).
13. See id.
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this pill available?" Again, the pill is a single compound, Delta-9-THC,
and marijuana itself is composed of over 300 different substances. I also
do some traditional Chinese medicine studies and people say you cannot
get the same benefit from a traditional Chinese herb that has been dried and
extracted and put into a pill. It has to be the whole herb, and it has to be
made into a tea or a concoction or a decoction.
Similarly, our patients said, "Delta-9-THC or Marinol® is not the same
as marijuana plus, I cannot control the effect if I swallow the pill as well as
if I smoke it." And, in fact, if you look at the pharmacokinetics if you
swallow THC as a pill, it is not very well absorbed from the stomach. The
peak concentration is slowly reached and it lasts for a much longer time.
When you smoke it, the THC comes in very quickly and disappears more
rapidly. Also, when taken by mouth, one of the breakdown products of
Delta-9-THC is an 11-hydroxy product, also a psychoactive agent. So,
people who take the pill orally often complain that they are more zonked
than if they smoked.
For all these reasons, patients were turning to marijuana and turning to
the buyers' clubs. The Community Consortium felt that it was our obliga-
tion to look at what our patients were doing and to study it to see: (1) if it
was safe and (2) if it might in fact be effective. So, in 1992, we began to
develop a clinical trial to look at marijuana compared to Marinol® in pa-
tients with the AIDS wasting syndrome. We planned the trial in collabora-
tion with the FDA because I needed to get a special Investigational New
Drug number from the FDA to do this work.
The study was approved by the UCSF Institutional Review Board, and,
because we were dealing with a controlled substance in California, it also
had to be approved by the Research Advisory Panel of California, or the C-
RAP. The C-RAP also approved our study and my next step was to get my
Schedule I license so that I could prescribe the marijuana in this study.
At the time we were working with a collaborator who had made a con-
nection with a Dutch marijuana grower who grows marijuana for medicinal
purposes. He was going to give us three different strengths of marijuana
for the study as well as $50,000 to conduct a forty-patient clinical trial. I
sent off my application to the the Drug Enforcement Administration
(DEA), to get my Schedule I license in April of 1994, and I didn't hear
anything from them directly. A few months later, the FDA told me, "Don-
ald, the DEA is not going to give you a Schedule I license, because they are
not in favor of you importing marijuana across international borders from
the Dutch grower." That sounded reasonable and I said, "Well, do you
have any other ideas?" They said, "Seek a domestic source." I said, "Well,
do you have any clues on who that would be?" They said, "Go to NIDA,
the National Institute on Drug Abuse, because they supply marijuana for
people doing clinical trials." That's true, but NIDA supplies marijuana
mainly for people who are trying to show that it does bad things to people's
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lungs, chromosomes, motivation, etc., and they had never really been asked
to supply marijuana for a study that may show that it has a benefit.
Our trial was designed to give patients in an outpatient setting either
Marinol® or three different strengths of inhaled marijuana to see if they
gained weight or increased their appetite, and also to see what happened to
their immune systems. We were going to look at hormone levels, because
there is a concern that marijuana could decrease testosterone levels in men
and testosterone is important for building lean body mass.
So, we were going to do a pretty good study I thought. I wound up
sending it to Dr. Alan I. Leshner, the Director of the National Institute on
Drug Abuse, in August of 1994, asking for 5.7 kilograms of NIDA's mari-
juana. NIDA was rather slow to respond to me. An investigative reporter
in San Francisco called them in January 1995. She got somebody to an-
swer the phone saying, "Oh no, we have no intention of providing mari-
juana for a study that may show that it has a medical benefit." Four months
later, I got my official response from Dr. Leshner. He said he was sorry he
could not approve this study, and he could not give the marijuana for the
study because it was not scientific. Again, it had previously been approved
by the FDA, the University of California Institutional Review Board, as
well as the C-RAP, but he felt that it was not scientific. We were told, ul-
timately, that if we produced a study that got favorable peer review, Dr.
Leshner would reconsider providing us with marijuana from NIDA. Being
in academic medicine long enough, I knew favorable peer review meant
"send it off to the National Institutes of Health as a grant application."
So, one of the concerns that NIDA had is they did not want us giving
marijuana to outpatients. How did we know they were going to smoke it
and not share it? What if they got into a car accident, etc., etc.? They also
were concerned that if we were looking at weight gain we had no way of
knowing if people changed their caloric intake. We took all this to mean
that we should put our patients someplace where we could monitor them.
At San Francisco General Hospital, we have a General Clinical Research
Center, or GCRC, where patients can be housed. They get all their food
provided for them and made by dietitians who know how many calories are
in everything; everything is weighed and measured. We could also monitor
them smoking marijuana. So, we redesigned our study.
In the second study that we submitted, we were going to have fifteen
patients admitted for fifteen days to the GCRC; two fifteen day periods
separated by a three-week washout. During one time, the patients would
smoke marijuana, and during the other time, they would smoke marijuana
from which the THC had been removed, inert or placebo marijuana. Dur-
ing the study we would measure everything. We were going to measure
their caloric intake, their energy expenditure, their weight, their body com-
position and also look at the impact on the AIDS virus level in their blood-
streams, their immune systems, their hormones, their neuropsychiatric
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testing and their lungs. We were going to measure everything.
We were just looking for a grade; when you submit a grant to the Gov-
ernment you need a priority score. Some of them are fundable, some of
them are not. All we needed was a number. We submitted this grant in
May 1996, and we were very confident that this was a much better submis-
sion.
Two days after the large Dennis Peron buyers' club (Cannabis Buyers'
Club) was closed in August 1996, I got a little rip-and-tear envelope from
the Government saying that they received my grant. Unfortunately, they
reviewed it but they were not going to give it a score, which meant that
they felt that it was not worthy of scoring. We were somewhat dismayed at
this, because we thought this was a much better proposal. They said, "Wait
for a few months until you get your review sheets from the reviewer."
Again, the media started calling me and saying, "Donald, this surely must
be political." And I said, "No, no, no, this is science. This is a review by
my peers. At the National Institutes of Health, they put together these
committees to review the grants, and it's not politics at all. This is scien-
tific and there must have been something wrong with the grant."
When I got the reviewers' comments two out of the three reviewers
said, "We don't understand why they would consider studying such a toxic
substance." The third reviewer said, "Aren't you concerned that if patients
smoked marijuana in the setting of AIDS wasting that they may develop
high blood fat levels and hardening of the arteries?" Now patients usually
did not live long enough to have these concerns, so I was sort of shocked
that this was a so-called peer review estimation.
I went to my executive board, our scientific advisory committee and
our community advisory forum at the Community Consortium and said,
"Should we continue this, because this is now five, six years I've been
working on this? I have a life. I do other things. Maybe we should stop
here." They said, "Donald, they tell us 11,000 of our patients are smoking
marijuana, and they are obtaining it from the buyers' clubs. We need to
know if it is safe and effective."
Well, a lot of things have happened in the past few years in AIDS
treatment. The biggest are the cocktails, or the protease inhibitor contain-
ing regimens. These drugs are very sensitive to metabolism by the liver.
They require one of the liver enzymes, and many other drugs interact with
that system so you can lower or raise the level of the protease inhibitors in
the bloodstream, which will either make them less effective or perhaps
more toxic. Interestingly, the cannabinoids are metabolized by the same
enzyme system. So, in 1997, a little light bulb went on in my head and I
said, "What we will do now is show them safety. We will submit a grant
that will look for drug interactions between protease inhibitors and canna-
bis. We are going to look to see if smoking or swallowing THC impacts on
the level of the AIDS drugs in patients' blood streams."
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We designed another study where patients would be housed, again, in
our GCRC for twenty-five days. They would be assigned either to smoke a
marijuana cigarette three times a day before meals, take a Marinol® pill or
take a Marinol® placebo. By having a placebo arm we can determine
whether there is any impact of cannabis at all. And, by having smoked ver-
sus oral, we can tell whether there is a difference in this interaction, should
it exist, if people smoke cannabis or swallow it.
Again, we submitted a grant to the Government asking for $1 million.
Many things had happened in the political side of this, including General
McCaffrey's statement, after Proposition 215 was passed, saying that doc-
tors in California and Arizona should not talk to patients about marijuana.
14
This really organized medicine, I think, for the first time to say, "You can't
tell us what to do." People got angry. The NIH put together a Blue Ribbon
panel to study the question of medical marijuana, although the results of
that panel were not made public for six months after the panel's delibera-
tions. Their conclusion was that more research was necessary. Many peo-
ple were calling for more research, including the editors of the New Eng-
land Journal of Medicine, and we just happened to be there again with this
new proposal which the Government actually liked. So in August 1997,
they gave us a very good score, sent us $1 million and 1,400 marijuana
cigarettes.
So, we have now begun, as Steve mentioned, the first federally-
sanctioned clinical trial of medical marijuana in the country. I just met
with Dr. Leshner who came out and visited us and was very happy. He told
me another study had been approved to look at glaucoma and, I think, mul-
tiple sclerosis. But we are now halfway done with our study and, hope-
fully, we will have results by the end of the year. Again, the end points that
we are looking at in this study are safety. We are looking at the levels of
the protease inhibitor in the bloodstream, the levels of the virus, impact on
the immune system and the impact on hormones.
We are also looking at efficacy. We are not going to enroll sixty-four
patients and fail to see if it increases their appetite, increases their weight
and changes their body composition (i.e., do they put on fat or do they put
on lean muscle mass?). Again, it has been a struggle. I always said if the
science outlives the politics, eventually, we may, in fact, be able to do this
study. I am really pleased and delighted to be conducting this study. It is a
very important clinical trial. We hope that if we do show safety, and per-
haps if there is some efficacy of the smoked marijuana, that we will be able
to continue on and do a series of studies looking at the impact of marijuana
in patients with HIV both on appetite and nausea, and also on pain relief,
particularly of the peripheral neuropathy, or painful feet, that our patients
14. See Conant v. McCaffrey, 172 F.R.D. 681, 688 (N.D. Cal. 1997).
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get. This condition often requires treatment with morphine and other very
strong analgesics.
Colleagues at the University of California, San Francisco in the neurol-
ogy program have discovered that THC has specific effects against neuro-
pathic pain which opiates do not have. So, in fact, there could be a time
where people might use cannabis as a pain relief agent before moving on to
stronger addictive narcotic agents. I think we are at a very exciting time in
the history of the use of these agents. The Institute of Medicine also did a
one-year study of medical marijuana, commissioned by General McCaf-
frey, our drug czar, despite the fact that they did one in 1982, and con-
cluded more research was necessary. This one-year study was just com-
pleted, 15 and I understand that it appeared on a web page today.16 The
results of the one-year study are that more research is necessary. So, we
are here to tell you that research is being done and I look forward to the rest
of the panel's discussion. Thank you.
STEVE HEILIG, MODERATOR
Thank you Dr. Abrams. So everybody was saying research was indi-
cated, and it's finally underway. It takes time, though, and as you also
heard between the lines there, it is hard to keep 'pure' science pure when
you are talking about something like marijuana. So, in the interim, while
we are waiting for the research, the implementation and interpretation of
the status of marijuana for medical purposes in California is still very much
in the hands of attorneys, politicians and those who are charged with inter-
preting and implementing the law. So, we are going to turn now to attor-
neys. The first one is Dan Abrahamson, the legal director for the Lindes-
mith Center. The Lindesmith Center has an office here in San Francisco
and is basically a drug policy think tank and action group. They really try
to raise the level of debate about drug policy in the states. I met Dan when
Proposition 215 passed and he was very interested in having some educa-
tional forums on this and being involved in the implementation. So, he is
intimately close to, at least in San Francisco and elsewhere, what this really
means, and is trying to, in a logical sense, implement Proposition 215.
15. See MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE (Janet E. Joy et al.,
eds., 1999).
16. See National Academy Press, Marijuana and Medicine, Assessing the Science Base
(visited Mar. 21, 2000) <http://www.nap.edu/catalog/6376.html>.
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DANIEL ABRAHAMS ON17
Thank you, Steve. I want to add a few points to the history of medical
marijuana that Dr. Abrams set out. Then, I will provide a rough overview
of where things stand with respect to the legality of medical marijuana in
California and in other states around the country, as well as some of the le-
gal interplay between the federal and state governments.
Dr. Abrams noted that marijuana has been used for medical purposes
for almost 5,000 years. It appeared in the 1764 English dispensatory,
which was the pharmacopoeia in England in the 1700's. Over the last hun-
dred years or so, there has been basic research on medical marijuana, but
the research has not reached the level of sophistication of which we are ca-
pable today. Nonetheless, several high-level commissions, in this and other
countries, have examined marijuana and their conclusions should not be ig-
nored. One of the first was the LaGuardia Commission 8 composed of sci-
entists, doctors, a corrections commissioner and public health experts who
were appointed in 1938 following the passage of the Marijuana Tax Act of
1937-the wellspring of the federal government's war on marijuana. The
LaGuardia Commission presented its detailed findings in 1944 and con-
cluded that marijuana use does not cause crime, antisocial behavior or lead
to an acquired tolerance of the drug. Nevertheless, the conclusions of the
LaGuardia Commission, although still valid today, were swept under the
rug so that the federal government could intensify its war on marijuana.
In 1970, as Dr. Abrams noted, marijuana was assigned to Schedule"Iof
the federal Controlled Substances Act.19 That meant that in the eyes of te
federal government, marijuana had a high potential for abuse and no ac-
cepted medical use. One year later, in 1971, President Richard Nixon ap-
pointed the National Commission on Marihuana and Drug Abuse, also
known as the Shafer Commission.2 Nixon appointed this commission
thinking that this panel of his hand-picked experts would conclude once-
and-for-all that-counter to the claims of the Woodstock generation-
marijuana was a dangerous substance, and sanction the continued war on
marijuana and its users. The Shafer Commission proved a disappointment
to the President and in 1972 recommended that marijuana use be "depoliti-
17. Daniel Abrahamson received his J.D. from New York University Law School. He is
currently Director of Legal Affairs for The Lindesmith Center in San Francisco, a policy
research institute founded in 1994 as a project of the Open Society Institute that focuses on
broadening the debate on drug policy and related issues. Additional information about the
Center can be found at <http://www.lindesmith.org>.
18. See L. Grinspoon & J. Bakalar, MARIJUANA THE FORBIDDEN MEDICINE 11 (1993).
Grinspoon and Bakalar's book explains how New York's Mayor LaGuardia appointed a
committee of scientists in 1938 to study the medical, sociological and psychological aspects
of marijuana use in New York. See iL
19. 21 U.S.C. § 801 et seq.
20. See MARIHUANA: A SIGNAL OF MISUNDERSTANDING, FIRST REPORT OF THE NATIONAL
COMMISSION ON MARIJUANA AND DRUG ABUSE (1972).
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cized, deglamorized and decriminalized." 21
Between 1970 and the mid-1980's, thirty-five states in this country
passed laws permitting physicians to prescribe marijuana to patients. Most
of those laws lay dormant on the books. Nonetheless, the majority of states
in one way or another, at one time or another, officially recognized the
medical efficacy of marijuana. In 1976, Robert Randall, a glaucoma pa-
tient, successfully petitioned the federal government to obtain medical
marijuana for his disease under an experimental drug treatment protocol.
22
Subsequently, thirty more patients received permission from the feds to re-
ceive marijuana to treat their illnesses, ranging from cancer, to painful bone
and degenerative disorders, to HIV/AIDS. The marijuana was grown on
federal land in Mississippi, by federal marijuana farmers, rolled up into the
cigarettes that Dr. Abrams referred to and sent through the federal mail to
patients around the country. Despite the program's apparent success, in the
late 1980's the Bush administration stopped admitting new patients to the
medical marijuana program, declaring that the program sent the wrong
message to the public, especially children. This is a central refrain of the
federal War on Drugs, and in particular, the war on marijuana. In fact, it is
the very response offered by the federal government to the passage of
Proposition 215 by the voters of California in November 1996.
Proposition 215, also known as the Compassionate Use Act, is a short
law--only about one-half page long.23 On its face, it is not very complex
or detailed. Indeed, it is pretty straightforward. It provides that patients
suffering from serious illnesses, who have a recommendation from a Cali-
fornia physician stating that marijuana might be beneficial to their health,
can legally grow or possess medical marijuana or have a caregiver grow or
obtain marijuana for them. Also, doctors who recommend marijuana to
their patients in the course of their care are not in violation of state law. In
passing Proposition 215, California voters were not legalizing marijuana.
Rather, they were simply saying, "We are not going to use our limited law
enforcement resources to pursue sick people who benefit medically by us-
ing marijuana, or arrest the persons who are trying to help these patients get
well."
In other words, California voters decided to take a 'baby step' back
from the larger War on Drugs. In so doing, Californians were not changing
or bucking federal law. Federal law prohibits marijuana use and Proposi-
tion 215 does not alter that fact. Californians merely chose not to devote
their limited resources to enforcing the federal war against marijuana when
21. RIcHARD J. BONNIE & CHARLES H. WHITEBREAD II, THE MARIJUANA CONVICTION: A
HISTORY OF MARIHUANA PROHIBITION IN THE UNITED STATES xi (1999); set also LYNN
ZIMMER & JOHN P. MORGAN, MARIJUANA MYTHS, MARIJUANA FACTS 7-9 (1997).
22. See MARIJUANA, MEDIcINE AND THE LAW 27-28 (Robert C. Randall ed., 1988).
23. See CAL. HEALTH & SAFETY CODE § 11362.5 (West 2000).
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that war was waged against the sick and dying. So, for the law students in
the audience, you see that the passage of Proposition 215 did not create a
conflict with federal law.
Now, the federal government did not like the message it felt was sent
by Proposition 215. However, absent a direct conflict of laws, the federal
government could not sue California and have Proposition 215 declared
unconstitutional under the Supremacy Clause. Officials in Washington,
D.C. thought long and hard about how to put an end to the Compassionate
Use Act before other states enacted similar measures. In all their brilliance,
the Beltway bureaucrats decided to wage a war on the doctors of Califor-
nia. On December 30, 1996, in a press conference in our nation's capitol,
Attorney General Janet Reno, Secretary of Health and Human Services,
Donna Shalala, Director of the Office of National Drug Control Policy,
General Barry McCaffrey (our "Drug Czar"), and Tom Constantine, Ad-
ministrator of the Drug Enforcement Administration, announced to the
television cameras that any physician in California who recommended
marijuana to a sick or dying patient could be punished under federal law.24
Specifically, they threatened physicians with the revocation of their federal
license to prescribe controlled substances medicine, revocation of their
contracts with Medicaid so they cannot get reimbursed with federal monies,
and/or prosecution under federal law. Any one of these sanctions could put
a doctor out of business. That was the federal government's response to
Proposition 215.
As Dr. Abrams suggested, and I think as Alice Mead will discuss fur-
ther, doctors in California were outraged that federal officials (none of
whom were physicians) were telling them what they could and could not
tell their patients. The American Civil Liberties Union, a San Francisco
law firm and The Lindesmith Center, agreed to represent California's phy-
sicians and patients in a class action suit against the federal government to
vindicate their First Amendment rights. The class was headed up by a
group of leading physicians specializing, primarily, in oncology and
HIV/AIDS and several prominent patients who used medical marijuana
pursuant to a doctor's recommendation. We went to court in January 1997,
and in April 1997, Federal District Court Judge Fern Smith ruled that the
federal government likely had violated the First Amendment in threatening
the doctors.2 The court proceeded to issue first a temporary restraining or-
der and then a preliminary injunction against the government, enjoining
government officials from threatening or punishing physicians for recom-
26mending marijuana to certain classes of patients. The case, Conant v.
24. See 62 Fed. Reg. 6164 (1997). See also Tim Golden, Doctors are Focus of Plan
Fight New Drug Laws, N.Y. TIMES, Dec. 23, 1996 at A10.
25. See Conant v. McCaffrey, 172 F.R.D. 681, 687 (N.D. Cal. 1997).
26. See id.
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McCaffrey, continues to be litigated towards a permanent injunction as we
sit here today.27
There are complicated issues still to be resolved. Judge Smith said that
doctors should be able to speak openly with their patients, but she also
stated that doctors cannot aid and abet patients in obtaining marijuana be-
cause that would be illegal under federal law. But what does it mean for a
doctor to "aid and abet" a patient in obtaining marijuana? For reasons I'll
briefly discuss, that is a gray area that needs to be clarified.
Steve Heilig, in his opening remarks, discussed the new medical mari-
juana dispensary on Market Street, a few blocks from the law school. I
think it is useful to spend a moment talking about what these so-called
"buyers' clubs" probably cannot do in light of Judge Smith's ruling that
doctors cannot "aid and abet" patients in obtaining marijuana. Cannabis
buyers' clubs operate in order to insure that legitimate patients can safely
obtain medical-grade supplies of the medicine recommended by their phy-
sician. The best way for these dispensaries to accomplish this laudable
goal is to ensure that their clientele are bonafide patients-that they are se-
riously ill, are being treated by a doctor and that their doctor recommends
marijuana for their medical use. Can the person in charge of dispensing
medicine at the buyers' club pick up the phone and call the doctor to con-
firm that the person in front of them is a patient in need of marijuana? Or
that the patient is using an appropriate amount of marijuana? Or that the
patient is ingesting it in an appropriate manner given their medical condi-
tion (e.g., drinking it in a tea verses eating it in a brownie)? As a lawyer, I
find myself in the uncomfortable position of telling the clubs, "No, you
may not pick up the phone and call that doctor, even if doing so enables
you to run a tighter ship and better serve your clients." Similarly, I feel
compelled to counsel physicians that they risk violating federal law if they
have good reason to know or believe that saying or writing something for a
patient will likely facilitate that patient's acquisition of marijuana. We are
now wandering in that gray area of aiding and abetting a federal crime.
In short, the federal government is driving a wedge between doctors'
ability to inform their patients about-what might help them, and the ability
of patients to obtain the treatment that their doctors recommend where that
treatment involves marijuana. To be sure, there are other difficulties with
Proposition 215. Vernon Grigg will speak more about the day-to-day en-
forcement issues surrounding the law for patients, prosecutors and cops on
the beat. But let me conclude with a post-Proposition 215 update.
Proposition 215 remains the law in California. And to the consterna-
tion of the federal government, other states are following suit. A few
months ago Alaska, Washington, Oregon and Nevada passed medical
27. As of March 2000, the parties were litigating disputes related to issues of discovery.
[Vol. 11: 1
28
marijuana laws. Unlike Proposition 215 which was quite short, the ini-
tiatives in these other states were quite detailed in many respects, and pro-
vided much more guidance to patients, doctors and state officials. The
laws set out more clearly what medical conditions qualify a patient for
marijuana. Some of the laws establish registries where state health agen-
cies will verify the patient's status and issue photo I.D. cards to patients
who can then prove to law enforcement officials that they are legitimate
users of medical marijuana. The laws also set forth permissible amounts of
marijuana that patients can lawfully possess. Additionally, the laws estab-
lish a "preponderance of the evidence" standard, such that if patients are
caught with more marijuana than what is allowed under those states' laws,
patients are able to assert an affirmative defense and introduce evidence
showing that the additional marijuana is medically justified.
There was also a medical marijuana initiative placed on the November
3, 1998, ballot in the District of Columbia.29 In response, Republican Con-
gressman Bob Barr of Georgia added an amendment to the federal budget
which provided that no federal money could be used in any way to advance
medical marijuana or to decriminalize marijuana. 30 Because D.C. is utterly
dependent on federal money, this amendment sought to nullify the D.C.
initiative. Although it would cost only $7.23 to push the button to tabulate
the D.C. ballot results, the federal government refused to pay the money,
and it refused to accept offers by others to pay it. All because the voters of
D.C. might 'send the wrong message' if they voted to decriminalize medi-
cal marijuana. The ACLU again went to federal court, suing the federal
government for deprivation of First Amendment rights of the D.C. elector-
ate.31 The battle continues.
28. See ALASKA STAT. § 17.37.030 (Michie 1999); 1999 OR. LAWS 825; WASH. REV.
CODE § 69.51.040 (1999). Maine's initiative is the most recently adopted. See Medical
Marijuana: Maine Approves Initiative, AM. HEALTH LINE, Nov. 4, 1999. Voters in Nevada
will decide on their initiative in November 2000. See Mike Kalil, Legality of medical
marijuana addressed, LAS VEGAS REV. J., Feb. 20, 2000, at lB.
29. Washington to Vote On Marijuana Use, N.Y. TIMES, Sept. 18, 1998, at A26
30. Omnibus Consolidated Appropriations Bill of 1998, Pub. L. No. 105-277, § 171,
112 Stat. 2681-150 (1998).
None of the funds contained in [the District of Columbia Appropriations
Act] may be used to conduct any ballot initiative which seeks to legalize
or otherwise reduce penalties associated with the possession, use, or
distribution of any schedule I substance under the Controlled Sub-
stances Act... or any tetrahydrocannabinols derivative.
Id.
31. In September 1999, the federal district court ruled that the Barr Amendment does not
prevent the Board from computing and certifying the results of the referendum on Initiative
59. See Turner v. District of Columbia Bd. Of Elections & Ethics, 77 F. Supp. 2d 25 (D.C.
1999). The votes were counted and the initiative was approved 69 percent to 31 percent.
See Bill Miller & Spencer Hsu, Results Are Out: Marijuana Initiative Passes, WASH. POST,
Sept 21, 1999, at Al.
MEDICINAL MARIJUANAWinter 20001
HASTINGS WOMEN'S LAW JOURNAL
STEVEN HEILIG, MODERATOR
Thank you Dan. Now we are going to hear from two people who have
the unenviable task of trying to interpret this in terms of enforcement.
Vernon Grigg is head of the narcotics division here in the San Francisco's
D.A. office. He is a graduate of Yale Law School and is going to tell us
what it is like to try to figure out how to interpret this great gray area that
we are hearing about today.
VERNON GRIGG
3 2
Good afternoon, I am the managing attorney of the narcotics unit for
the San Francisco District Attorney's Office, and I can be really brief. It
sucks to try to interpret this law. I am not going to kid you, it really does. I
think speaking to the law students in the group, one of the things that I can
say to you is that this law is a model on what happens when clear lines are
not drawn, and when efficiencies and other considerations are not taken
into account when drafting legislation.
The thing is a mess; it really is. It leaves so may subjective decisions
along the way-determinations that have very severe implications for peo-
ple's lives. In many cases, the people who are making these decisions are
not necessarily qualified to be making assessments regarding whether or
not it is reasonable for a person to possess a certain quantity of marijuana,
whether or not someone really is a caregiver and things of that nature. It
falls on our desk, because we are responsible for all the local prosecution of
narcotics cases. We are ultimately the ones who decide whether or not you
are going to face the power of the state in court trying to put you in jail.
With that by way of a preface, let me begin with a description of what our
experience has been like.
First of all, District Attorney Terence Hallinan has long been a sup-
porter of medicinal marijuana, from the very earliest stages of proposed
legislation. During his time on the Board of Supervisors, he was in favor
of the seriously ill having access to medicinal marijuana. It was with some
great anticipation that the results of Proposition 215 came in positively and
we thought, "Okay, this is good because it will put medicine in the hands of
sick people," or at least that was the thought. Very quickly we learned just
how complicated this whole thing can become.
Throughout our office we are presented with approximately 1,000
cases a month to make prosecution decisions regarding a range of viola-
tions, from heroin sales in the South of Market area to marijuana sales in
the Mission. Needless to say, efficiency matters. When you are going
32. Vernon Grigg received his J.D. from Yale Law School. He is currently an Assistant




through those kinds of numbers, you have to know what is legal and what
is illegal conduct. When you have to stop and study in great depth exactly
what is going on and try to figure out whether or not it is a violation of the
law, it can really encumber the system. When there is a charge in front of
you of a person who was caught in his car with some marijuana and he has
his I.D. card, and he says "I'm a medicinal user," you look at the circum-
stances, and you make your charging decision. That is easy.
The more difficult case is when you are awakened at 3:00 a.m. You
have twenty or thirty law enforcement officers at a location wanting a
search warrant based upon their belief that there is marijuana cultivation
going on inside. There may be some evidence that the location is involved
in some way, or has asserted itself to be involved, in the provision of me-
dicinal marijuana. I think that can illustrate just how people not necessarily
well qualified to make determinations have to make decisions regarding
whether law enforcement goes in, seizes the plants and arrests people.
There are always dangers both to law enforcement and to the people inside
residences when there is a forcible entry, so, you sort it out in the morning,
or you find some other way to decompress the crisis and you deal with it all
the next day. You make your decisions and you try to move on.
One of the things that complicates matters for us is that we can talk
about medicine, we can talk about how to fix this law, but the reality is that
marijuana in this country is a tremendously profitable business. Marijuana
generates tremendous revenue. Medicinal marijuana is a subset that, hope-
fully, will not become imbued with the same kind of economics as illicit
marijuana. The prohibition on marijuana has driven marijuana prices and
profit margin so high that I have talked to crack cocaine dealers who
stopped selling crack cocaine and started selling marijuana. They say it is a
lot safer to sell marijuana, the penalties are not as severe and the profits are
higher. Rather than selling to crack addicts and people on the street, with
the accompanying dangers and hassles, a dealer can sell marijuana. In the
illicit, non-medicinal marijuana market, many of the users tend to be afflu-
ent and can be functional. Marijuana, except at the highest levels, is not
characterized by a whole lot of violence surrounding its trafficking. So
dealers can make more money and live longer selling marijuana than they
can selling crack.
The amount of money involved raises other issues that complicate the
medicinal marijuana analysis: issues of security, issues of supply and ac-
cess, whether or not it should be on a for-profit or not-for-profit basis if it is
for medicinal use. Let me draw a scenario so it is easier for you to go
through this with me. Let us assume that law enforcement gets a report of
water leaking through a ceiling. A landlord goes in to try to find out why
water is leaking into an apartment. He has reason to believe they are culti-
vating marijuana upstairs and that the hydroponics system is leaking, so he
calls the police.
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Now, sometimes in San Francisco that call to the police is motivated by
the fact that the tenant growing marijuana upstairs has been there for ten
years and is paying $550.00 a month for rent, and the landlord wants him
out. So we have to always be very careful not to be used to settle landlord-
tenant disputes. If someone grows two plants of marijuana, and the land-
lord goes in there and says, "He is cultivating drugs, and he is going to get
my place seized. We want him out." That, of course, opens up the rental
property.
But let's say it is actually a substantial operation, 100-250 plants, and
the police show up. They look inside and see bright glowing lights. They
subpoena the PG&E bills and find out that the guy has been using $1,000
worth of electricity every month. They can smell it through some air vents
and apply for a search warrant. They get the search warrant and go in
there. It is peaceful. They take all the plants; they take everything. They
come down, and they charge a case. The person comes in the next day and
says, "Ah, I am a caregiver." The caregiver designation is one of the most
tricky, thorny, unclear areas that we have to deal with. We are really not in
the business of prosecuting sick people who are legitimate users and who
are just using marijuana; we are just not interested in that.
It is the sellers that we are interested in. Because there is so much in
marijuana, and the illicit market is so large and well-developed, we must
then determine the terms on which they are selling, to whom they sell, what
kind of money they make, what kind of money they are investing, their
historical involvement with medicinal marijuana and the provision of
medicine, and so on and so forth. You get into a myriad of aspects of the
person's "operation"-financial, medical and so on. We must ask, for ex-
ample, "What kind of proof do you have? Who are you a caregiver for?"
And it can be very difficult to make a decision-very difficult to know for
sure, because in many cases, you have a hybrid operation. You can have
someone who provides medical marijuana to sick people, but also sells
some on the side to whoever wants to buy it.
You also have situations where people sell marijuana to people who
eventually sell it on Haight Street and then donate marijuana to clubs to
provide cover. They can say, "I give X amount every month to these clubs
so you can't come after me." Sometimes what they are giving away is not
of the same quality as what they are selling. They are giving away the stuff
that is not as good. It is a very muddled and difficult task to determine
whether or not someone's primary focus is profit in the illicit market, or
whether or not it is medicinal provision. Then the question arises of why
should it be his primary purpose? That is an arbitrary distinction. Like-
wise, what if his primary purpose is medicinal marijuana and a little tiny
teensy side purpose is making some money? That is criminal conduct too,




So the point of the matter is there are no standards. Everything is gray
with this law from start to finish, and that makes it really difficult now. We
are trying to implement it in a common sense, humane manner designed to
effectuate the purpose of the will of the voters. Terence Hallinan is very
clear: 80% of San Franciscans voted for medicinal marijuana, 69% of those
people who went to the polls on Proposition 215 voted for medicinal mari-
juana.33 We wanted to bring that reality to San Francisco, but without any
definite, hard standards it is very hard.
So, that is just the case of the privateer, someone who is in their apart-
ment growing some marijuana. They are giving some away or selling
some. Should they just cover expenses, or should they make a profit?
Some will argue that pharmaceutical companies make a profit, so why
shouldn't someone who grows marijuana make a profit? Then you have
the club situation. The Court of Appeals has said that the club model is not
34what was contemplated by Proposition 215. This was the basis upon
which the Market Street clubs had to close.
The law seems to contemplate almost a family farm. It contemplates
that an individual who is sick will be out there in his backyard cultivating
his own marijuana. That is completely unrealistic, particularly someplace
like in the City and County of San Francisco. So again, you have drafting
problems, perhaps unavoidable, that inhibit the ability of law enforcement
to really make this law meaningful.
However, we are trying to improve upon that. Just last week I attended
a meeting with Bill Lockyer and a number of other law enforcement people
from throughout the state to try to figure out what is to be done about
Proposition 215. The people around the table were from both ends of the
spectrum-people with pending cases for cultivating marijuana and people
prosecuting them on behalf of the Attorney's General office. It is the hope
of law enforcement and state officials that some kind of rational interpreta-
tion can be brought to bear on the law, and that we can figure out how and
what to do. I am going to close on that, and I look forward to your ques-
tions, because I think therein we can target exactly what it is that you want
to go into. If you are going to have a supply of medicinal marijuana, the
most important factors to be considered are: (1) Where is it going to come
from? (2) Under whose authority is it going to be regulated? Regulation
has to be a part of it, given the profit that is available on the illicit market.
So, with that, I will sit down, and we will hear from some of the other
speakers.
33. See Sabin Russell, Federal Judge Orders Closure Of Pot Clubs, S.F. CHRON., May
15, 1998, at A19 (stating that the initiative passed by an 8 to 1 ratio in San Francisco).
34. See People ex rel. Lungren v. Peron, 59 Cal. App. 4th 1383, 1392 (1997).
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We are going to hear a little bit more from the law enforcement side
from Robert Elsberg, who reminded me that we debated each other during
the campaign about Proposition 215. He has been the president of the
state's Narcotic Officers Association and is senior special agent in that bu-
reau. So, I expect he may focus a little bit more on the issues of the entire
state in trying to again interpret what is a very gray area.
ROBERT ELSBERG35
Let me clear up a little bit, actually I have two titles. I am here today
representing the California Narcotic Officers Association (CNOA), where
about 7,000 police officers represent the federal government, state govern-
ment and local government. We are all out working for law enforcement
agencies throughout the year arresting people that are illicitly growing,
selling and manufacturing drugs for illicit purposes. Our primary role is
actually to put on training for peace officers. But because it is very hard to
specialize training in this very narrow topic, at the same time we have been
very legislatively active.
I face a unique situation. My boss a few weeks ago was Dan Lund-
gren, and my boss today is Bill Lockyer. So, those of you who know these
people know that they are totally different people, and they have different
ideas about what we should be doing in this state. I do work for the Cali-
fornia Attorney General and am a special agent in charge of the California
Bureau of Narcotic Enforcement which encompasses about nine counties in
the Bay Area. But, I am here today to speak about CNOA because I am not
sure what Bill Lockyer would say about medicinal marijuana, just like I am
not sure about everything that Dan Lundgren might have said about mari-
juana.
We clearly are here to suppress drugs, enforce the state and federal
laws and put people that put other people on drugs in jail. We have a big
drug problem in this country, and we have a big problem in this state. We
probably have been called the capital of the problem more often than any
other state in the nation for many of the drugs that are illicitly sold are pro-
duced in this county. We really care about preventing illicit drugs from
getting onto the street. Marijuana was a topic we did not deal with a whole
lot a few years ago and today, I think I spend probably 50% of my time
talking on this one subject.
First of all, let's just talk about the law. It has been argued or discussed
35. Robert Elsberg is Senior Special Agent in Charge of the Bureau of Narcotic En-
forcement at the California Department of Justice. As past President and Executive Board
Member of the California Narcotic Officer's Association, he served as a legislative chair-
person against Proposition 215. Mr. Elsberg has thirty years of law enforcement experience
at the Attorney General's office.
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how gray the area is, but I am not sure you all know exactly how gray it is.
The way that the law was drafted, you only need a verbal recommendation.
It does not say that you even have to see your doctor but you could possibly
get a recommendation over the telephone or by some other means. It is a
recommendation. It does not say how old you have to be to get this rec-
ommendation. You could be a kid; you could be an adult. If you were to
go to a doctor for a prescription other than marijuana you would be looked
at and prescribed something. For your treatment you would probably have
to go back again and you would get a certain amount of the drug to last for
a certain amount of time.
Not with this law. With this law you basically are on your own. You
grow your own, you grow as much as you want, you use as much as you
want, no one tells you when to quit using this drug, you can use it for the
rest of your life. These are some of the problems that we in the Narcotic
Officers Association had with this particular law. This law was so broad
that here we are trying to prevent marijuana from getting to our kids, from
getting out for illicit purposes, and this law was broadening the availability
and the exposure. Now, with the more abundant amount of marijuana there
could even be a reduction in prices of marijuana.
There is a program each year called CAMP (Campaign Against Mari-
juana Planting). Every year during the marijuana season, teams go out and
raid the gardens primarily in Humboldt, Del Norte and Mendocino coun-
ties, but also throughout the state. Since Proposition 215 was passed, the
seizures have been in record numbers. They have never been bigger than
they are today. Clearly, Proposition 215 is having that kind of impact on
growing and it is not all going for medicine. So, CNOA is very concerned
about this whole issue. We are not trying to be doctors; we know nothing
about medicine. There may be a few who do but most of us do not. We are
not scientists, and we are not here to tell you it is not a medicine because
we honestly do not know. But, we are here to try to prevent marijuana
from getting to people on the street for illicit purposes. We support, which
is kind of hard for some people to believe because they thought we were
against everything, but we really do support research, and we were one of
the few groups last year that was with Senator John Vasoncellos actually
supporting a bill36 to try to do more studies for marijuana as a medicine.
Unfortunately, the bill never made it through.
One of the problems that we see is a clear tension between the federal
and state laws. Before we were born, there were all kinds of leeches that
were used to cure everything. We have things that are medicine now, like
cocaine. I mean it went through the system and became a medicine. Now,
we have something called marijuana and it is having trouble getting
36. See The Marijuana Research Act of 1999; S.B. 847, 1999-2000 Sess. (Cal. 1999).
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through the system to be shown that it is a safe and effective substance that
can be a medicine. We would like to see that cleared up but, until it is, we
oppose marijuana being used by anyone for any purpose. It is a violation
of federal law.
If I go out on the street with a federal agent and we find somebody with
a lot of marijuana, the federal government can arrest that person and then
prosecute in federal court. We, state officers, would go to the District At-
torney to see if we could file charges. Obviously, if there was a rebuttal
presumption and the defendant could show the marijuana was for medical
purposes, he or she would not be convicted of the offense. We have can-
nabis buyer's clubs all over the state, and we were laughing there is one out
here on Mission Street. Now that's a joke. We basically have a Court of
Appeals decision holding that a cannabis buyer's club is not a caregiver.
So, we have people out there now actually violating the law; and we have
people that are very sensitive to the fact that there are some sick people out
there that may be getting some good benefits from this substance, and we
do not want to disturb the cart.
But, in essence, this whole thing is not going away. It is not going to
get any better until we do the research. Once we do the research, it is our
recommendation that if it is proven to be safe and effective that we treat
marijuana just like any other substance, and we make it a controlled sub-
stance Schedule II, III or IV. Then a doctor can legally prescribe the sub-
stance just as he now does for any other sickness. A doctor could then feel
comfortable writing a prescription for marijuana to treat something, but
again that is not the way it is now.
So we have a big fight between various factions and we are spending a
lot of the federal, state and local taxpayers' time, the workers' time and the
politicians' time. We are just slowly starting to find and make some prog-
ress through work such as Dr. Abrams' scientific studies. I think we all
want to see this thing come to an end, but I do not think any of us want to
see these open businesses selling to everybody and anybody. All they have
to do is walk in and pick up their pot. These are profit-making ventures.
We have evidence from several cases that we have worked on that even if
they do not charge for the marijuana, they charge other types of fees so
even if the marijuana is free they are making money in a different way.
I do not want to be repetitious, but, by and large, I think that both sides
of the counter here are on the same page regarding wanting to put this thing
to rest, wanting to do the scientific studies, wanting to finally determine
once and for all if marijuana is safe and effective. We would like both the
federal and state governments to be on the same page and to treat marijuana
just like any other medicine. Then patients would not have to worry about
how to get marijuana or how to grow it. They could just have it delivered
to their doors, or they could go to the local pharmacy. Thank you.
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As has been mentioned in addition to law enforcement having diffi-
culty in interpreting what they can and cannot do in California in regard to
medicinal marijuana, physicians in California obviously have a lot of un-
certainty as well. Alice Mead is legal counsel with the California Medical
Association. I have worked with her on all kinds of issues through the
years and know that there is probably no one better to give a summary on
exactly what the official line of what attorneys should be telling physicians
regarding what they should or should not do. Keep in mind that what phy-
sicians really want to do is practice medicine and they do not want to get




Thank you, I'm glad to be here today. It seems like I have spent a lot
of my time talking about medical marijuana for the last few years. I repre-
sent the California Medical Association (CMA) which has about 30,000
practicing physicians. We are the largest state medical association in the
country, and I have handled this issue because I specialize in the area of
end-of-life care. So, it seemed appropriate for me to examine medical
marijuana since so many people who appear to benefit from the use of
marijuana are unfortunately in an end-of-life disease situation.
Proposition 215 posed a terrible dilemma for organized medicine.
CMA did not support Proposition 215 because as you have learned from
the other speakers, organized medicine is very committed to the scientific
process. We are committed to clinical trials like Dr. Abrams'. The way a
new drug is introduced into the population is through such clinical trials
where safety and then efficacy are demonstrated and the FDA gives its ap-
proval. We were very concerned that this was the introduction essentially
of a new drug, despite its honorable lineage. It had not gone through that
scientific process, so it was being introduced by popular fiat. We were
concerned that this would set a somewhat dangerous precedent for the fu-
ture if other initiatives could be enacted by the people that allow untested
drugs to be used at the state level.
We want to see hard clinical evidence that something is safe and effi-
cacious. Physicians want to benefit their patients, but they do not want to
give or recommend something that may be a nullity. It may not actually
help the patient, it may give them false hope that they are going to be bene-
fited, or it may have some undesirable effect on this particular medical
37. Alice Mead received her J.D. from University of Santa Clara School of Law, and her
L.L.M. from Yale Law School. She is currently legal counsel for the California Medical
Association.
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condition or this particular patient. Physicians certainly do not want to pre-
scribe something that might be contaminated, where the dosage is not con-
trolled, or where the source is not regulated.
For all these reasons CMA did not support Proposition 215, although it
knew that there were many physicians who were discussing medical mari-
juana with their patients and who had determined that, in their professional
opinion, it might be helpful for those patients. We have consistently sup-
ported further research in the area, and our policy has become a bit broader
over the last few years, to the point where we do support a "limited distri-
bution to appropriate patients by closely regulated sources." However, we
have not exactly identified what those sources should be if they are not
pharmacies. We think that the structure of distribution by cannabis clubs is
somewhat dangerous. Some dispensaries were run very professionally, and
the quality of the cannabis was probably consistent and good. Others,
however, were not. Institutions that are not under any single supervisorial
authority, or not even under local authority, run the risk of inadvertently
providing contaminated material to patients.
So, we wanted further research, and we applauded Dr. Abrams' work.
38We sent a letter in his support to the federal government. It was not lost
on CMA that there have been political obstacles to the research being con-
ducted. We see that it is a double bind, but nevertheless, the research has
not been conducted-that is still the bottom line. We would like to dimin-
ish those obstacles. For example, why should Dr. Abrams have to submit a
grant proposal just because he wanted to use NIDA marijuana, which is not
even of very good quality. Its THC content is not very high, and it does not
give him a choice of different THC contents. Why should he have to use it,
just because he uses their marijuana? Why shouldn't he be able to import it
from some reliable source somewhere else? Why should he have to seek
funding from NIH? Those seem to us to be an unreasonable obstacles, and
I think the AMA has written a letter to NIDA suggesting that there should
38. CMA also recently wrote a letter of support to the federal government on behalf of
the work of GW Pharmaceuticals, Ltd., a small pharmaceutical company founded by a Brit-
ish physician, Dr. Geoffrey Guy. GW is dedicated to the research and development of non-
smoked delivery mechanisms (including a sublingual spray and inhaler) that x ill be used to
deliver pharmaceutical-quality whole cannabis extracts. GW will provide standardized dos-
ages of known and reproducible compositions, that are designed to meet the rigorous scien-
tific standards applicable to pharmaceutical products. Its approach was endorsed by the In-
stitute of Medicine's 1999 report on cannabis, Marijuana and Medicine: Assessing the
Science Base, and has been enthusiastically received by the federal Drug Enforcement Ad-
ministration and Director McCaffrey's office. GW hopes to make prescription medicine
available to patients within 3-4 years in this country. CMA in its letter stated that the GW
approach "will address the concerns of both health care providers-many of Nxho do not be-
lieve that a medicine should be smoked-and patients-who desire the ability to titrate their
dosages to achieve therapeutic effect." Letter from John C. Lewin, MD to the Honorable
Barry R. McCaffrey, September 20, 1999; see also U.K. Medicinal Cannabis Project (vis-
ited Mar. 24, 2000) <http://www.medicinal-cannabis.org>.
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be no need.39 The grant application process is basically an added obstacle
over and above the FDA approval process, and FDA approval should be
sufficient to require NIDA to provide marijuana to a researcher. So, we
definitely oppose these additional obstacles that seem to us to be more po-
litically motivated than anything else. FDA approval should have been suf-
ficient to allow Dr. Abrams to have obtained marijuana from essentially
whatever legal and reliable source he could find.
Now, having said that we did not support Proposition 215 for all the
reasons discussed above about the scientific process, and that we support
further research, CMA still believes that physicians ought to be able to talk
to their patients now and have full physician-patient discussions about
whatever the physician thinks might be beneficial to the patient. We were
disturbed when Barry McCaffrey, Director of the Office of National Drug
Central Policy, came out with his statement about going after doctors who
recommended marijuana.4° We thought, "They cannot mean that doctors
can't talk with patients. They surely can't mean that. They know about the
First Amendment too."
We applauded the lawsuit that was filed, but we did not join it because
we simply could not believe that the federal government meant what it ap-
peared to be saying. We contacted Director McCaffrey and talked at great
length with his office. We said, "You surely do not mean that there cannot
be full physician-patient discussions. This is protected by the First
Amendment. This is what physicians do." They said, "That's right. They
can have discussions but they cannot take any additional steps for the pur-
pose of assisting the patient in getting marijuana because that is aiding and
abetting, and that is not protected by the First Amendment." We said, "We
agree. We think they can have full professional discussions in a bona fide
physician-patient relationship." We went home and wrote extensive
guidelines for physicians about what we thought they could do and say and
what they could not do, including making confirmations to buyer's clubs,
because that was taking the "next step". If a physician writes a letter or has
a telephone conversation with a buyer's club, the question may be asked,
"Why did you tell that buyer's club that the patient is your patient?" If the
physician tells the buyer's club that he or she recommended marijuana or
39. On May 21, 1999, the Department of Health and Human Services (HHS) announced
a change in this policy. HHS stated that, effective December 1, 1999, HHS would allow
research-grade marijuana to be made available, on a cost-reimbursement basis, for approved
research projects other than those directly submitted to and reviewed by NIH through the
regular grant approval process. See Richard Sisk, U.S. to Deal Reefer But It'll Only Sell for
Research Use, DAILY NEWS (New York, N.Y.), May 22, 1999, at 2. In theory, at least, re-
search that is not funded by NIH may qualify for and receive research-grade marijuana.
However, Dr. Ethan Russo, the first researcher to seek research marijuana under this new
policy, was turned down, despite the fact that his protocol had already been approved by the
FDA.
40. See Michael Pollan, The Pot Proposition, N.Y. TPAEs, July 20, 1997, at 23.
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that the patient has a serious disease, what is the only credible answer-to
assist the patient in getting marijuana? So, that runs the risk of crossing
over the line to aiding and abetting.
We did not recommend that physicians do that, but we were specific
about all the things that physicians could do. We believed on the basis of
our conversation with McCaffrey's office that there could be a full patient-
physician discussion, and the physician could share any anecdotal experi-
ences of other patients similarly situated. Obviously, there were not clini-
cal trials but there was anecdotal evidence that could be shared, including
whatever possible benefits and risks the physician could share. The physi-
cian could even say, "In your case it might be worth a try." That is a rec-
ommendation. We said that the physician should write all that in the medi-
cal record. This is what doctors normally do when they have on their
physician hats. They have a full physician-patient discussion and record it
in the medical record. And, that is what they should do in this context.
The guidelines were distributed. But, in the courtroom during the First
Amendment litigation, the federal government said they would not sub-
scribe to these guidelines. We were dismayed because we thought we had
agreement from the federal government.
Unfortunately, the lawsuit is continuing and the federal government is
continuing to fight. All we can surmise is that they think physicians cannot
have full physician-patient discussions, and that these are not protected by
the First Amendment. Otherwise, I assume some sort of reasonable settle-
ment would have been reached, and that is very disturbing. If there were
another unapproved substance such as St. John's Wort, a full discussion and
recommendation would be would be allowed. Physicians should be able to
discuss these options with patients and share whatever information, knowl-
edge or experience they have without fear of some kind of retribution.
I fear that even if the lawsuit is ultimately successful and a permanent
injunction is issued, if the injunction looks anything like the preliminary
injunction, physicians will be able to discuss or recommend marijuana, but
they will not be allowed to aid and abet.41 The many questions I have re-
41. However, a recent Ninth Circuit panel decision may have expanded the assistance
that physicians and others can lawfully give to certain medical marijuana patients. In the
course of an appeal in a civil lawsuit brought by the federal government in an attempt to
close a number of the clubs, the Court stated that, despite the federal Controlled Substances
Act, the clubs could legally dispense marijuana to patients who meet the criteria for "medi-
cal necessity." The concept of medical necessity applies to patients who (1) have serious
medical conditions for whom the use of cannabis is necessary in order to treat or alleviate
those conditions of their symptoms; (2) will suffer harm if they are denied cannabis; and (3)
have no legal alternatives to cannabis for effective treatment of their medical conditions be-
cause they have tried other alternatives and have found that they are ineffective, or that they
result in intolerable side effects. See U.S. v. Oakland Cannabis Buyers' Cooperative, 190
F.3d 1109, 1114 (9th Cir. 1999). The federal government has sought rehearing and rehear-
ing en bane. CMA filed an amicus brief in support of the panel's ruling on medical neces-
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ceived from physicians have centered around where the line is drawn. Un-
fortunately, as lawyers are always saying, it is not clear. Physicians are
very uncomfortable with that, because their entire practices are at stake.
So, despite the preliminary injunction, I get calls from different counties
where physicians are reluctant to have any discussions at all about mari-
juana or to write anything in the medical record. Additionally, I have had
conversations with cannabis clubs about why the physician cannot confirm
that the patients are real patients, and that is a legitimate concern. If a can-
nabis club wants to be run as professionally as possible, it wants to be sure
that it is distributing to genuine patients. They want to be sure they have
real physicians with real recommendations, but how do they find that out?
We did think of a reasonable solution. Under state law, patients have
the right to get access to their medical records. They can go into the office
and say, "Physician/Nurse/ Receptionist, I want a copy of my medical rec-
ord or part of it." The patients have a right to get a copy. So we said, on
the one hand, physicians should have full discussions. Physicians should
document those discussions in the medical record, including the statement
about how marijuana might be worth a try. Then, if the patient comes in
and gets a copy of the medical record, that is the patient's business. The
patient has done so unilaterally, exercising his or her rights under state law.
What the patient does with that medical record, including going to a canna-
bis club, is up to the patient and does not involve the physician. We
thought that would work nicely, and I think in some places it does work
reasonably well. However, some cannabis clubs are still concerned that
there is a possibility of a patient forging a medical record. It is difficult to
come up with the perfect solution that can protect all parties in that case.42
A few other areas have also been problematic. For example, the Medi-
cal Board, which has a disciplinary power over physicians, has issued some
uncertain guidelines which say that the Board will not pursue a physician if
the physician treated marijuana like a standard drug, did a good faith prior
exam of the patient, is not over-prescribing, got informed consent of the
patient and demonstrated in the medical record the basis of his or her rec-
ommendation. Well, how do you get informed consent from the patient?
There have not been clinical trials, so the risks for any particular medical
condition are sort of unknown. How does a physician establish a scientific
basis for his/her recommendation in the medical record so the Medical
Board will be satisfied that this was a reasonable recommendation? What
sity.
42. During the first half of 1999, Attorney General Bill Lockyer established a Task Force
of Medical Marijuana. See Maura Dolan & Mary Curtius, Medical Need a Factor in Pot
Cases, L.A. TIMES, Sept. 14, 1999, at Al. The Task Force, of which CMA was an active
member, developed legislation, carried by Senator John Vasconcellos (S.B. 848) to try to
implement Proposition 215 in a way that would protect bona fide patients from unnecessary
and onerous prosecution. That legislation failed because of lack of support from Governor
Davis. See id.
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scientific literature can physicians point to?
I have gotten those questions across my desk, and it is difficult for phy-
sicians to know how to protect their practices if they want to make a rec-
ommendation. As part of the informed consent process, do they need to
warn the patient that there is no protection for the patient under federal law,
and that the patient might still be prosecuted? Indeed, in some counties the
patient might even be prosecuted under state law. I cannot tell you how
many requests for assistance I have received from patients with recommen-
dations in counties where supposedly they were told, "We do not apply that
law here."
Doctors are not really accustomed to having to make those kinds of
warnings to patients. If a physician fails to make a warning to a patient and
the patient gets prosecuted or the patient has an untoward reaction that no-
body would have known of because there were no clinical trials, is the phy-
sician covered by malpractice insurance? I have spoken with some mal-
practice carriers and they said, "That is a really good question. We do not
know if we would provide coverage. We might provide a defense with res-
ervation." I know of at least one case where the Medical Board is looking
at a physician who made several recommendations for conditions that are
specifically spelled out in Proposition 215. So, the medical profession is
very sympathetic to the needs of patients who have serious medical condi-
tions. We are currently in a state of such uncertainty on so many fronts that
we need a way of ironing this out so that all parties are protected and phy-
sicians are able to help their patients in the way they are at least reasonably
accustomed and which provides protection to everyone involved. Thank
you.
STEVEN IEILIG, MODERATOR
Thank you Alice. I should mention I actually brought a handout that is
the official position of the San Francisco Medical SocietY43 on what physi-
cians can do and what model they should follow and actually it's very close
to what Alice has outlined in terms of what we call the "medical records"
model. On the other side is a little editorial I wrote in the Chronicle called
When Newt Gingrich Spoke Out For Medical Pot44 that you might find in-
teresting. We come now to Marsha Cohen who is a professor at Hastings
and also has been the head of the State Board of Pharmacy. Thus, she
straddles these various worlds, and we have saved her for last because she
is going to tell us how to solve all of the problems that have been detailed
here by the other speakers.
43. Steve Heilig, MEDICAL MARIJUANA UPDATE: Legal Developments and Practical
Considerations, 70 S.F. MED. 11 (1997).
44. Steve Heilig, When Newt Gingrich spoke out for medical pot, S.F. ExmINER, May




Thank you, I am not going to solve these problems by myself. I need
some political involvement here. Mr. Grigg said the thing is a mess. Of
course, it is a mess-it was passed by initiative. That is not an unusual
problem with the initiative process, because if something is put in an initia-
tive, you do not have to solve all the logical problems that a legislature
might look at.
Many people in this state were disappointed when they woke up the
day after election day and marijuana, at least for medical purposes, was not
really legal in California. As I was fond of telling the press at the time,
medicinal marijuana would not be legal in California unless we were also
to secede from the union. Federal law in this area could not be cancelled
by our initiative, however well intentioned. The other aspect of federal law
that the initiative did not cancel, and that has not been talked about very
much, although it has been touched upon today, is the authority possessed
by the Food and Drug Administration to determine which substances that
are intended to cure or ameliorate human disease are safe and effective for
their intended purposes, and thus may be legally distributed as drugs.
States cannot choose to distribute as a drug or approve as a drug something
which the federal government does not approve of. There were lawsuits up
to the Supreme Court of the United States on this issue a number of years
ago in the 70's on a substance called laetril which was a purported cancer
cure.
46
As you know from hearing other people, marijuana has not been ap-
proved for sale as a human drug, except in the form of Marinol® which is
considered marijuana itself. Marinol® is a Schedule I controlled substance.
Someone mentioned that Schedule I controlled substances are dangerous.
Actually, the legal definition of a Schedule I drug is a drug for which there
is a high potential for abuse, no currently accepted medical use in treatment
in the United States and a lack of accepted safety for use under medical su-
pervision. The federal government and, in particular, the Drug Enforce-
ment Administration, has brought this mess upon itself. It is a very expen-
sive legal dilemma we are in because everybody is spending money on
lawyers and we have a whole bunch of states involved; five I believe.
So, we have a bunch of states which are defying the federal govern-
ment. Of course, all of their laws will fall to federal law as our has, but
45. Marsha Cohen received her J.D. from Harvard Law School. She currently teaches
health law as a professor at Hastings College of the Law, and lectures for the Pharmacy
Program at the University of California, San Francisco. Previously she participated on a
review panel for the Department of Health Education and Welfare that investigated the
FDA's approval of new drugs, and later served as president of the California State Board of
Pharmacy for two terms.
46. See generally United States v. Rutherford, 442 U.S. 544 (1979).
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conservative medical opinion has favored reclassifying marijuana from
Schedule I into Schedule II. The editors of the New England Journal of
Medicine, certainly no radicals, editorialized about this in January of
1997.47 The definition of a Schedule 1I drug48 is one where there is a high
potential for abuse, a currently accepted medical use and abuse may lead to
severe psychological or physical dependence. A rescheduling petition for
marijuana was filed in 1972.49 It was not denied until the early 1990s. Ju-
dicial review upheld the DEA's decision in 1994.50 A new petition has
been filed and was cited in Judge Breyer's opinion in one of the pot club
scrimmages. The new petition was referred to the Secretary of Health and
Human Services at the end of 1997, according to that Breyer opinion.5 '
In order to prove that there is a currently accepted medical use to re-
schedule a drug from Schedule I to Schedule II, you must be able to get the
drug to test it. You need the drug so that you can prove that there is, in
fact, a legitimate medical use. And, as you heard from Dr. Abrams, the
federal government has been less than cooperative in making marijuana
available for this testing, although it is totally obvious that it ought to be
tested to determine whether it is appropriate for the various conditions for
which it appears to provide at least systematic relief. It is only clinical
testing that can distinguish between people's observations that a drug is
helping and real proof, due to the serious placebo effect with any drug.
Controlled clinical studies are needed. Those studies also need to de-
cide what are the appropriate dosages, what are the contra-indications, for
whom the drug would be dangerous and what drug interactions exist. All
of these considerations are important for the approval of a drug and for its
safe use; but until it is tested, there is no way to move it from Schedule I to
Schedule II. If marijuana is determined to be safe and effective, and again
they approved Marinolo which suggests that there is safe and effective use,
it should be made available like every other medication-by a prescription
from a licensed prescriber that would then be filled at a pharmacy by a li-
censed pharmacist.
I have been involved with pharmacists, as you know, and pharmacists
are important players in the drug distribution scene. As with other pre-
scription drugs, although the doctor chooses the drug, the pharmacists are
there to make sure that the drug is appropriate. They check interactions
with other drugs the patient may be taking. Allowing one drug to be dis-
47. Jerome P. Kassirer, Editorial: Federal Foolishness and Marijuana, 336 NEW ENG. J.
MED. 336, 336 (1997).
48. See 21 U.S.C. § 812(b)(2)(1994).
49. See Alliance For Cannabis Therapeutics v. Drug Enforcement Admin., 15 F.3d 1131,
1133 (D.C. Cir. 1994)
50. See generally id.
51. See United States v. Cannabis Cultivators Club, 5 F. Supp. 2d 1082, 1105 (N.D. Cal.
1998).
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pensed outside of the system without the protection these professionals
provide seems to make absolutely no sense. The problem is, how do we
get from this expensive mess to a proper determination of marijuana's
medical use, appropriate review by the Food & Drug Administration and
then, if it is approved, to rescheduling?
I doubt that this stalemate will be broken anytime soon by federal ini-
tiative, although on November 5, 1998, the Drug Enforcement Administra-
tion (DEA) published in the Federal Register a proposal to change the
scheduling of Marinol® from Schedule II down to Schedule III, which is
very interesting.52 It is also interesting that in that document they say they
are re-evaluating Marinol® at the request of the Assistant Secretary for
Health. The DEA added that they are not asking to move marijuana from
Schedule I down; they made sure that their proposal has no impact on that.
Although, obviously, they ought to be related scientifically.
I am hoping that California's new political leadership will be willing to
invest some of its time and talent and the state's time, talent and energy to
getting rid of this stalemate. I would like to see Governor Davis and Attor-
ney General Lockyer say to the federal government, "We will commit state
government resources to supervising the testing of marijuana for legitimate
medical purposes and settle this matter in return for a couple of guarantees
for some cooperation by the federal government."
Obviously, the first thing the feds have to do is assure access to ade-
quate supplies of marijuana for that testing, or give California permission
to cultivate marijuana for that single purpose. Also, I would like them to
agree to do the testing. Then, if the FDA is willing to admit or to approve a
"New Drug Application" (NDA) for marijuana for some medical purposes,
and the DEA would agree to reschedule marijuana, rather than saying,
"You reschedule, then we will get the NDA's out there." I also hope they
would ask the FDA to cooperate in reviewing the design of the clinical tests
before they are run to assure that the resources the state would invest in this
whole process are not wasted. In return, the state government would make
the further commitment that once medical marijuana was available in
pharmacies, of course it would not just be California but throughout the
nation, the leadership in California would introduce legislation with the
purpose of returning California law and marijuana to conformity with fed-
eral law. In other words, we will go to the legislature to reverse the loop-
hole which Proposition 215 put into our drug laws in return for getting true
medical marijuana.
You might wonder where the drug companies are, because there is
money to be made here. However, marijuana is a generic product, and the
52. See Schedule of Controlled Substances: Rescheduling of Synthetic Dronabinol
(Martinol®; Tetrahydrocannabinol in Sesame oil and Encapsulated in Soft Gelatin Capsules)
From Schedule II to Schedule 111, 63 Fed. Reg. 59751 (proposed Nov. 5, 1998).
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drug companies cannot get patents. The companies get their patents before
they even get their INDs.53 Their investigational new drug information is
out there because they do not want anyone to jump in ahead of them in the
patent office. They want their intellectual property protection before they
move forward so they have a period of time when they have exclusive
rights to the product. Because it is a generic product, and also a very con-
troversial product, the major drug companies have not been willing to sup-
port the testing needed to determine the safety and efficacy of marijuana.
This, of course, presents a problem for the state, but frankly there are
philanthropists who have been plowing in huge amounts of money to get an
initiative passed. If so, they might be willing to support the testing of the
drug so that no more initiatives would be necessary. It would seem that
California could certainly look into doing this. We have a lot of California
institutions with the talent to conduct the necessary clinical tests; we have
Dr. Abrams, and we have the school of pharmacy at UCSF, which is the
premier pharmacy school in the nation and has some drug testing capaci-
ties. Drug companies might be interested in other methods of administra-
tion, given the serious health problems incident to smoking any substance.
Testing should obviously include other methods of administration that
circumvent the digestive system such as nasal sprays and skin patches. I
understand there some small entrepreneurial drug companies that are look-
ing into this, and private firms might support testing of that nature as the
resulting products might well be eligible for patent protection. Obviously,
lots of money and energy have been spent on trying to decide what is legal
here. I think we need to appeal to Governor Davis and Attorney General
Lockyer to make a pitch to their friends in Washington. At least now we
have a state government that has broken bread with the federal government.
California and the federal government's mutual resources could be better
diverted to a far more productive task; namely, trying to determine whether
medical marijuana ought to take its place in the medical armamentarium
along with many other substances that are far more dangerous than mari-
juana but also provide relief from human suffering. Thank you.
53. IND, investigational new drug, is a phase in the process of FDA approval for new
drugs. At this stage the drug may be used on humans, not for treatment but for investiga-
tion. See PEMR HUTr & RICHARD MERRmL, FOOD & DRUG LAW, 513-16 (199 1).
106 [Vol. 11: 1
